SBH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SBH is not a good buy right now. Price action is weak (bearish momentum) and the stock is sitting just above key support (~14.92). With no Intellectia buy signals today and mixed options positioning, the higher-probability move is more chop/down unless SBH quickly reclaims ~16.09 (pivot). For an impatient buyer, I’d hold off on buying until either (1) a clean bounce off 14.92 with momentum improvement, or (2) a breakout back above 16.09; otherwise the near-term downside risk toward ~14.19 is too immediate.
Trend/momentum: Near-term bias is bearish. MACD histogram is -0.0845 (below zero) and negatively expanding, signaling weakening momentum. RSI(6) at 36.28 is approaching oversold but not showing a confirmed reversal yet. Moving averages are converging, consistent with consolidation after weakness rather than a clear uptrend. Key levels: Current price 15.08 is just above S1 = 14.915 (critical near-term support). A break below S1 increases odds of a move toward S2 = 14.191. Overhead resistance is the pivot = 16.086, then R1 = 17.256.
Intellectia Proprietary Trading Signals
• Product/news momentum: Launch of ion® 24K collection with damage-repair claims and additional ion® tools planned for spring 2026 (supports brand/story).
• Upcoming event catalyst: Earnings on 2026-02-09 (pre-market) can re-rate the stock if results/guide surprise.
• Street support improving: Two bullish actions on 2026-01-21 (Raymond James upgrade to Outperform; TD Cowen Buy with higher target) can support sentiment/flows.
• Technical pressure: Bearish MACD and price sitting just above 14.92 support raises near-term breakdown risk toward 14.19.
• Options positioning skew: High Put/Call OI (2.01) suggests persistent hedging/caution.
• Mixed analyst backdrop: Morgan Stanley remains Underweight (though it raised its target previously), reflecting skepticism about sustained EBIT upside if topline stays subdued.
• Pattern-based short-term expectation: Similar-pattern stats imply ~-1.24% over the next month (modestly negative skew).
Latest reported quarter: 2025/Q4 showed modest but improving fundamentals. • Revenue: $947.1M, +1.29% YoY (low growth, but positive). • Net income: $49.9M, +3.90% YoY. • EPS: $0.49, +8.89% YoY (profit growth outpacing sales). • Gross margin: 52.17%, +1.80% YoY (margin expansion is a clear positive trend).
Recent trend: Analyst tone has improved meaningfully in January 2026. Raymond James upgraded SBH to Outperform with a $19 target and called it a top SMID-cap value pick for 2026, citing store improvements and a more consistent growth profile. TD Cowen reiterated Buy and raised target to $18. Wall Street pros: Improving execution narrative (store upgrades), steady beauty category trends, and margin expansion. Wall Street cons: Ongoing concern about limited topline growth and whether EBIT upside is sustainable (echoed by Morgan Stanley’s Underweight, despite its target increase to $13).
